Englander Institute for Precision Medicine
News & Events

News & Events

Join our frequent seminar series, case conferences, consortium meetings, and more!

The Urgent Need for Better Stroke Care

February 7, 2019

We are pleased to introduce you to Hye-Yeon Choi, M.D., M.S., Ph.D., a stroke neurologist from Seoul, South Korea. Dr. Choi is a visiting Assistant Professor of Physiology and Biophysics at Weill Cornell Medicine and a new Member of the Englander Institute for Precision Medicine.

Please Welcome Cora Sternberg, M.D.

January 25, 2019

The Englander Institute for Precision Medicine (EIPM) is excited to announce that world-renowned medical oncologist Cora Sternberg, M.D., has joined our staff as Clinical Director.

Machine Learning and the Immunopeptidome

January 8, 2019

Kevin Michael Boehm and colleagues from the Englander Institute for Precision Medicine at Weill Cornell Medicine have just published a new paper on how machine learning can be used to expand our understanding of the immunopeptidome.

The new paper, “Predicting peptide presentation by major histocompatability complex class I: an improved machine learning approach to the immunopeptide,” was published on January 5, 2019 in BMC Bioinformatics.

The Power of Collaboration

December 24, 2018

Collaborations between the Englander Institute for Precision Medicine (EIPM), Cornell University in Ithaca, and Cornell Tech are important to the future of precision medicine. To highlight the intellectual rewards of collaboration, we are pleased to introduce two young Ph.D. students from Cornell University who are spending significant time at the EIPM in New York City working on cutting-edge research projects.

Question: Please tell our readers about your research. 

Collaborating to Save Women’s Lives in Ghana

December 18, 2018

Dr. Davis is Assistant Professor of Cell and Developmental BiologyDepartment of Surgery, and Scientific Director of the International Center for the Study of Breast Cancer Subtypes, Weill Cornell Medical College. She is co-author of more than 20 peer-reviewed scientific journal articles.

New Breakthrough for Cancer Patients

December 12, 2018

The US Food and Drug Administration last month granted accelerated approval to a new cancer drug for adult and pediatric patients with solid tumors that have a specific genetic mutation detectable through Oncomine Comprehensive, an advanced Next Generation Sequencing (NGS) test co-developed by EIPM and the Weill Cornell Medicine Pathology department.

Meet Dr. Bishoy Faltas

November 26, 2018

Dr. Faltas is Assistant Professor of Medicine, Cell and Developmental Biology at Weill Cornell Medicine, and Director of Bladder Cancer Research at the Englander Institute for Precision Medicine.

We hope you enjoy learning more about the work of Dr. Faltas and his team. 

Please provide a brief overview of your background and work.

Mentoring Future Scientists

November 21, 2018

At the Englander Institute for Precision Medicine, we take our commitment to mentoring young scientists and encouraging the next generation of investigators very seriously.

So when the directors of the World Science Academy, a pre-college program for gifted New York City high school students, approached us to host more than 100 local students and teach them about our work and mission, we quickly accepted and together developed a program that would be interesting and informative. 

EIPM’s 2018 Precision Medicine Symposium

November 21, 2018

The Englander Institute for Precision Medicine’s (EIPM) Symposium fueled innovation and collaboration, bringing together nearly 200 faculty, students, and research staff last Thursday, November 15th. The inaugural event, “Innovations and Emerging Opportunities in Personalized Medicine,” featured speakers across areas of expertise from Weill Cornell Medicine, Cornell University, Cornell Tech, and NewYork-Presbyterian Queens. The full day of presentations covered topics of Novel Therapeutics, Technological Advancements, Drug Target Discovery, and Big Data Integration.

New Pathway Created to Reduce Skin Cancer Risk

November 6, 2018

New research published today in Science Signaling on mechanisms that control skin pigmentation reveal new pathways that could increase the pigmentation of skin and reduce the risk of skin cancer, the most common form of cancer in the United States.

A person’s skin color is determined by the amount and type of melanin in their cells. The production of melanin is influenced by the pH of melanosomes, which is more acidic in lighter skinned people.

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021